Key facts
- This page summarizes Johnny John's Form 4 filing for DELCATH SYSTEMS, INC. (DCTH).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Jan 2024, 16:22.
Johnny John - 08 Feb 2023 Form 4 Insider Report for DELCATH SYSTEMS, INC. (DCTH)
- Reporting relationship
- SVP CLINICAL DEV & MED AFFAIRS
- Issuer ticker
- DCTH
- Reported as of
- 08 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jan 2024, 16:22:21 UTC
- Prior SEC filing
- 15 Aug 2022
- Next SEC filing
- 21 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gerard Michel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Johnny John filed Form 4 for DELCATH SYSTEMS, INC. (DCTH) on 26 Jan 2024.
Change
- Previous filing in this sequence was filed on 15 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DCTH
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +46,800
- Change %
- Price
- $0.000000
- Shares after
- 46,800
- Date
- 08 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,800
- Exercise price
- $4.67
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 8, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions ofthe Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended).